Clinical Diagnosis

Prevent Blindness has designated November 18 to 24, 2024, as the 5th annual Thyroid Eye Disease (TED) Awareness Week. The week aims to raise awareness of TED's symptoms, impact on vision and mental health, and new treatment options. Educational resources and expert-led episodes will support patients and healthcare professionals.

A recent cohort study revealed low adoption of FDA-approved AI-based diabetic retinopathy detection, with less than 5% of diabetic patients receiving ophthalmic imaging. Researchers emphasize the need for improved awareness, cost-effectiveness, and integration to increase diabetic retinopathy screening rates.

Peking University researchers have developed a deep learning-based, noninvasive choroidal angiography method that enables detailed 3D visualization of choroidal vessels from OCT scans. This technique could improve diagnostics for retinal diseases like macular degeneration, offering a safer alternative to traditional methods.

To educate the public—including parents, caregivers, and allied health professionals—Prevent Blindness is offering free educational resources, including fact sheets, social media graphics, web pages, and educational videos in both English and Spanish.

A group of German researchers has discovered how tiny eye movements and the density of photoreceptors assist in visual acuity.

A study led by researchers at the University of Birmingham finds AI-powered models can match ophthalmologists in diagnosing infectious keratitis, offering promise for global eye care improvements.

A recent paper reveals increasing rates of diabetic retinopathy in young patients with diabetes, sparking concerns over inadequate screening and management, especially among Black and Hispanic youths.

A team of researchers at Arizona State University has developed tools to aid in the diagnosis of myopic maculopathy.

Push to identify biomarkers for earlier diagnosis, new therapeutic targets.

Current Fuchs endothelial corneal dystrophy treatments include implanted cultured human endothelial cells.

Early diagnosis of NMOSD is key to preventing disability, improving survival.

Researchers train deep learning model on OCT scans to ID patients eligible for GA trials.

According to Genentech, faricimab-svoa is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness.

Optimizing corneal neurotization outcomes with cryopreserved amniotic membrane.

VISTA is a global randomly assigned, controlled, masked, multi-center pivotal study evaluating the efficacy, safety, and tolerability of 2 dose levels of AGTC-501 for the treatment of X-linked retinitis pigmentosa

Positive data from the GALE long-term extension study showed patients developed fewer new scotomatous points with 36 months of both continuous monthly and every-other-month treatment.

Researchers examined data of more than 200,000 people, some at an early stage of the disease and some without age-related eyesight issues

According to the company, it will finalize its Phase 3 development plans following an End-of-Phase 2 meeting with the FDA.

Low birth weight, blood transfusion, necrotising enterocolitis, bronchopulmonary dysplasia and antenatal steroid and surfactant therapies are among the factors that affect the development of ROP.

Investigators put forth a list of considerations for surgeons ahead of lens removal in pediatric patients

According to a study, the research reveals that boosting a specific protein, IRAK-M, in retinal cells could offer a new and highly effective therapy for AMD

Authors pointed out that understanding this link may aid with genetic counseling or surveillance of affected individuals, potentially contributing to improved management and outcomes.

MELT-300 is a non IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg).

Schocket has been serving as Interim chair since July, 2022, and during that time has worked to establish best practices for the department, strengthening its academic programs and improving its financial viability.

Understanding how the intricate networks of blood vessels in the eye and brain are formed ultimately could inspire new treatments for conditions like diabetic retinopathy and stroke.

Ocugen is developing OCU410 as a 1-time gene therapy for the treatment of geographic atrophy. It utilizes an AAV delivery platform for the retinal delivery of the ROR Related Orphan Receptor A gene.

Office transitions to a portable vision diagnostic and patient engagement system.

According to ophthalmologists at the Colorado University School of Medicine, discussing mental well-being is a key part of effective treatment and improving care for patients.

The campaign will encourage, educate and empower the public to include vision and eye health as a part of their healthcare by asking them to share how eye care services and exams improved their vision and their daily lives.

Researchers at Massachusetts Eye and Ear led a phase 1/2 trial, which included 14 participants, that found the experimental treatment was safe and efficacious.